Skip to Content

Rhofade FDA Approval History

FDA Approved: Yes (First approved January 18, 2017)
Brand name: Rhofade
Generic name: oxymetazoline hydrochloride
Dosage form: Cream
Company: Allergan plc
Treatment for: Rosacea

Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults.

Development Timeline for Rhofade

Jan 19, 2017Approval Allergan Announces FDA Approval of Rhofade (oxymetazoline hydrochloride) Cream for Facial Erythema Associated with Rosacea
May 24, 2016Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.